Overview

XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and efficacy of XERECEPT® to dexamethasone (Decadron) a common treatment for symptoms of brain swelling (edema). This study is specifically aimed at patients who require chronic high doses of dexamethasone to manage symptoms.
Phase:
Phase 3
Details
Lead Sponsor:
Celtic Pharma Development Services
Collaborator:
Neurobiological Technologies
Treatments:
BB 1101
Corticotropin-Releasing Hormone
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate